About us

Our Future Health is an ambitious collaboration between the public, charity and private sectors to build the UK’s largest health research programme – bringing people together to develop new ways to prevent, detect and treat disease.

We are supported by charities and companies that conduct health research. We also received funding from UK Research and Innovation (UKRI) – the UK Government-funded body that invests in science and research – to help set up the programme.

Our governance

Our Future Health is a charity registered with the Charity Commission for England and Wales (charity number 1189681) and is a private company limited by guarantee (company number 12212468).

Our governance is designed to ensure the right level of challenge and advice is provided to the Trustees and Executives on key aspects of the programme. It ensures we can work effectively with the partners who help to fund, support and deliver our programme. It has also been developed to be in line with the Charity Governance Code.

Our Future Health governance boards including group boards, operational boards and advisory boards
Our Future Health governance structure

Our Future Health is governed by a Board of Trustees, who are ultimately responsible for the policies, activities and assets of Our Future Health and provide strategic leadership. Trustees serve on the Board in a voluntary capacity and do not receive remuneration. The Trustees of Our Future Health are:

  • Professor Sir John Bell
  • Mary Calam
  • Peter Chambré
  • Adrian Hennah
  • Sir Harpal Kumar
  • Dr Kemal Malik
  • Sally Osman
  • Dr Timothy Peakman OBE
  • Richard Sexton
  • Professor Fiona Watt
  • Guy Woolley

Advisory Boards

  • The Access Board is responsible for access to Our Future Health data, samples and participants and will report to the main Board
  • The Ethics Advisory Board monitors the development of Our Future Health to make sure it meets high ethical and governance standards across all its activities
  • The Diversity & Inclusion Advisory Board supports us in our aim to recruit participants from a diverse range of backgrounds
  • The Founders Board brings together the charity & industry partners who are co-funding the establishment of the Our Future Health programme
  • The Public Advisory Board comprises members of the general public and study participants to work with us on all aspects of Our Future Health
  • The Scientific Advisory Board is responsible for making sure that all Our Future Health research meets the highest ethical and scientific standards
  • The Technology Advisory Board has oversight of main Our Future Health platform technology solutions and decisions
  • The Implementation Board oversees decisions which will impact the delivery and implementation of the Our Future Health programme

Access Board and process

Our Access Board oversees access to Our Future Health data and samples. Members of the Access Board will include experts, members of the public and ultimately participants. They will only approve health-related research that is in line with the consent participants provided; is for public good and aligned to Our Future Health objectives; and that comes from researchers that have successfully completed our registration process.

The Access Board’s objective will be to enable access to Our Future Health resources for research studies, while ensuring we meet our commitments to participants and to the wider public interest. The Access Board will ensure that the access process is clear, robust and transparent, and implemented in a way which is proportionate, accountable and fair. The access process will be available on our website once it has been finalised.

Our Access Board will also make sure that projects are in line with our protocol, Ethics and Governance Framework and our ethical approval from the Health Research Authority.

All applications to use Our Future Health resources for research will be held to the same standards by the Access Board. This is the case whether an application is from Our Future Health partners or researchers at universities, government or the NHS.

We will maintain a public register on our website of all approved research studies so that participants, the wider public, researchers and policymakers can see how Our Future Health resources are being used and what studies are being carried out.

Full details about Our Future Health advisory boards and our governance are available in our Governance Manual.

Our funding

Our Future Health is an ambitious collaboration between the public sector, charities and companies that conduct health research and make the medicines, tests, equipment used to prevent, detect and treat diseases. You can read more details about the collaborations that support the Our Future Health programme on our partners page.

We are on target to raise resources of around £160 million from life sciences companies and disease-related charities. In January 2022 we announced £100 million funding from leading life sciences companies that are investing in and providing their expertise to support the design and successful delivery of our programme.

UK Research and Innovation Logo

Our Future Health also received initial funding of £79 million from UK Research and Innovation – the UK Government-funded body that invests in science and research. This funding is being used to set up and begin to deliver the programme.

↑back to top

Our team

Dr Andrew Roddam CEO of Our Future Health

Dr Andrew Roddam

CEO and Joint Chief Investigator

Andrew is an internationally renowned epidemiologist. He started his career at University of Oxford after studying there for a DPhil (Statistics) and has held a wide range of roles across both academia and industry applying epidemiological methods to advance the understanding of human disease. Andrew was most recently Vice President Data Strategy at GSK before joining as our CEO in April 2020.

Dr Raghib Ali

Chief Medical Officer and Joint Chief Investigator

Raghib is a clinical epidemiologist whose research is focused on the causes, prevention and treatment of diseases including diabetes, heart disease and cancer. He has spent the last 15 years at the Universities of Oxford and Cambridge and New York University working on similar studies, including UK Biobank, and is the Principal Investigator for the UAE Healthy Future Study. He is also a Consultant in acute medicine at the Oxford University Hospitals NHS Trust. He graduated from Cambridge University and holds postgraduate degrees in epidemiology and public health from the Universities of Cambridge, Oxford and London.

Michael Warren Chief Communications Officer of Our Future Health

Michael Warren

Chief Communications Officer

Michael joined Our Future Health in May 2020 and looks after our communications, policy and public affairs. He previously spent a year at the UK BioIndustry Association, following a 17-year career as a Senior Civil Servant responsible for communications teams at Innovate UK, the Department of Work and Pensions, the Home Office and the Prime Minister’s Office at No10 Downing Street. He studied psychology at the University of Durham.

Jo Roach Executive Director Platform & Products of Our Future Health

Jo Roach

Chief Operating Officer

Jo is a senior digital leader, COO, and start-up founder with broad experience in delivering digital platforms, products, and software services. She has successfully led operations and digital delivery in large corporate, start-up, public and charitable sectors over a career spanning more than two decades.

Dr Saskia Sanderson Chief Behavioural Scientist of Our Future Health

Dr Saskia Sanderson

Chief Behavioural Scientist

Saskia has over 20 years’ experience as an academic researcher conducting research in the field of psychology applied to genomics, including academic research appointments at University College London (UCL), the National Institutes of Health in Bethesda, US and at the Icahn School of Medicine at Mount Sinai, New York, US. Saskia holds a PhD in health psychology applied to genomics from UCL.

Dr Fiona Reddington Executive Director of Strategic Partnerships at Our Future Health

Dr Fiona Reddington

Executive Director of Strategic Partnerships

Fiona helped to establish Our Future Health in 2019 as our Interim Chief Operating Officer before taking responsibility for building our partnerships across the NHS, charities, and industry. She previously spent over ten years at Cancer Research UK where she was responsible for research portfolios in clinical trials, population research, prevention and early diagnosis. She holds a PhD (Neurophysiology) from Kings College London (UMDS).

Marko Balabanovic Technology Director of Our Future Health

Marko Balabanovic

Chief Technology Officer

Marko’s role is to help create a secure and scalable set of platforms for Our Future Health and create a high-quality data resource available for researchers. He has over 25 years’ experience leading technology teams and developing innovations in academia, corporations, and start-ups, in both the UK and US. He is also a Non-Executive Director on the Board of NHS Digital. He studied Computer Science at Cambridge University, and has a PhD in Computer Science (Artificial Intelligence) from Stanford.

Professor David Hunter MBBS MPH ScD FRACPHM Chief Science Adviser of Our Future Health

Professor David Hunter MBBS MPH ScD FRACPHM

Chief Science Adviser

David combines his work as our science adviser with his role as Richard Doll Professor of Epidemiology and Medicine and Director of the Translational Epidemiology Unit at the Nuffield Department of Population Health, University of Oxford.

Professor John Deanfield CBE BA Hons (Cantab), MB, BChir, FRCP, FESC, FACC

Professor John Deanfield CBE BA Hons (Cantab), MB, BChir, FRCP, FESC, FACC

Chief Medical Adviser

John Deanfield is Professor of Cardiology at University College London (UCL) and the Director of National Institute for Cardiovascular (CV) Outcomes Research (NICOR). He chaired the UK’s National Health Check Programme Review. He has been at the forefront of efforts to prevent heart disease and stroke from early intervention, which he has termed as “investing in your arteries”.

Dr Michael B Cook Executive Director of Epidemiology

Dr Michael B Cook

Executive Director of Epidemiology

Michael is a senior epidemiologist with broad and contemporary expertise in research, programme management, and scientific leadership. Michael was previously a tenured, Senior Investigator at the US National Institutes of Health. He has designed and conducted numerous studies to advance etiologic understanding, clinical management, and prevention of chronic disease.

Contact us

Our Support Team are available Monday to Friday 9am to 5pm on 0808 501 5634 (freephone)

If you would like to contact the Our Future Health team please email us at [email protected]

To contact our communications team for media and press enquiries please email [email protected]

↑back to top

Our aims and values

The overarching aim of Our Future Health is to help people live healthier lives for longer through better prevention, earlier detection and improved treatment of diseases. We aim to speed up the discovery of new methods of early disease detection, and the evaluation of new diagnostic tools, to help identify and treat diseases early when outcomes are usually better.

Our ambition is to recruit up to 5 million adults from across the UK to create a diverse and inclusive cohort of people who have consented to participate in the research.

The specific aims of our programme are:

  • To build a resource linking multiple sources of health and health-relevant information, including genetic data, on millions of people in the UK, to facilitate basic discovery research by academic and commercial researchers on early indicators of disease
  • To analyse the data in the resource to estimate personal disease risk information for participants, based on genetic and non-genetic information, and offer this estimated personal health information to participants who wish to receive it
  • To re-contact sub-groups of participants generally for additional samples, non-routine data and secondary studies over time
  • To re-contact participants on a risk-stratified basis (i.e. recall-by-genotype/phenotype or sociodemographic characteristics) over time specifically to enable secondary studies by academic and commercial researchers that is greatly enhanced by being able to identify highly enriched sub-populations/sub-cohorts of participants

Our values guide how we behave in all our work, our engagement with others and in our communications:

  • We must always be honest and transparent in our intentions and with the people and partners who contribute to this programme. The full benefits of this research can only be realised at scale and over time – it is essential that we build and retain the trust of all involved, by treating and protecting their contributions with the care we would expect.
  • We can only achieve our goal by creating new partnerships and ways of working, bringing together people and organisations that can contribute and empowering, encouraging and supporting them to do so.
  • We are ambitious and committed to reducing the impact of diseases for everyone. Our goal is to fundamentally change the way researchers prevent, detect and treat diseases. This requires us to be challenging and bold when necessary, but only in support of that goal and for the benefit of participants.
  • For everyone to be able to benefit from this research programme, it is critical that it represents all kinds of people. We aim to make potentially complex subjects and processes as accessible as possible, without compromising the results.

↑back to top